pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
BRISTOL MYERS SQUIBB CO ($BMY) · news · pharmadog
← back to BRISTOL MYERS SQUIBB CO
News mentioning $BMY
346
stories
Aug 31, 26
ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
biopharma dive
Aug 31, 26
Takeda, Protagonist score broad FDA nod in rare blood cancer, setting up $2B opportunity
biospace
Aug 31, 26
BMS’ neuro renaissance was built on back of Celgene mega-merger
biospace
Aug 31, 26
China poses increasing security risk as US biotech innovation edge erodes
biospace
Aug 27, 26
Opinion: STAT+: A bill is supposed to protect U.S. biotech from Chinese competition. But there’s a loophole
stat
Aug 26, 26
Cellares rebukes Bristol Myers' criticism of its cell therapy technology
endpoints
Aug 26, 26
BMS ends Cellares pact over cell therapy production problems, triggering layoffs
biospace
Aug 25, 26
Bristol Myers ends deal with Cellares, cell therapy manufacturer to reorg
endpoints
Aug 24, 26
Cellares, a cell therapy manufacturing specialist, to lay off 100 employees
biopharma dive
Aug 24, 26
Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand alone
biospace
Aug 23, 26
Why a Texas congressman believes Chinese biotechs are 'beating us on our ground game'
fiercebiotech
Aug 21, 26
Shareholder pressures Capricor; Lilly dives deeper into vaccines
biopharma dive
Aug 20, 26
Chutes & Ladders—Neumora shuffles leadership ahead of IND
fiercebiotech
Aug 20, 26
Chai tees up Bristol Myers Squibb AI antibody discovery collab
fiercebiotech
Aug 19, 26
Merck and Sarah Cannon team up to boost oncology trial efficiency
fiercebiotech
Aug 19, 26
Bristol Myers' partner Biokin says bispecific ADC clears fourth cancer trial in China
endpoints
Aug 18, 26
AstraZeneca scores in lung cancer; Sandoz inks a China deal
biopharma dive
Aug 18, 26
Merck and Sarah Cannon team up to boost oncology trial efficiency
fiercebiotech
Aug 17, 26
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
Aug 17, 26
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
fiercebiotech
Aug 14, 26
Cytokinetics brings patent suit against Bristol Myers, escalating rivalry
endpoints
Aug 14, 26
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
biopharma dive
Aug 14, 26
STAT+: PBMs agree to display TrumpRx drug prices
stat
Aug 14, 26
STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more
stat
Aug 14, 26
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
Aug 14, 26
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
stat
Aug 14, 26
BMS welcomes new multiple myeloma drug as generics batter current portfolio
biospace
Aug 14, 26
MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter
fiercebiotech
Aug 13, 26
FDA approves Bristol Myers' multiple myeloma successor
endpoints
Aug 12, 26
With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
biospace
← prev
page 7 of 12
next →